Current evidence suggests that inhibiting KIF4A can reduce MDSC recruitment and enhance cytotoxic T cell infiltration [9], providing a rationale for combining it with immune checkpoint inhibitors to overcome barriers in tumour immunotherapy resistance. The gene discussed is KIF4A; the disease is neoplasm.